Prof. Dr. Bernd Wullich



Organisationseinheit


Lehrstuhl für Urologie


Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 10 Go to next page Go to last page

Eckstein, M., Sailer, V., Nielsen, B.S., Wittenberg, T., Wiesmann, V., Lieb, V.,... Wach, S. (2019). Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. Laboratory Investigation. https://dx.doi.org/10.1038/s41374-019-0251-8
Wach, S., Brandl, M., Borchardt, H., Weigelt, K., Lukat, S., Nolte, E.,... Aigner, A. (2019). Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo. Molecular Therapy - Nucleic Acids, 16, 272-283. https://dx.doi.org/10.1016/j.omtn.2019.02.020
Kahlmeyer, A., Stoehr, C.G., Hartmann, A., Goebell, P., Wullich, B., Wach, S.,... Erlmeier, F. (2019). Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. Journal of Clinical Medicine, 8(5). https://dx.doi.org/10.3390/jcm8050743
Wullich, B., & Wiedemann, A. (2019). Geriatric urology (Geriatrische Urologie). Urologe, 58(4), 369-. https://dx.doi.org/10.1007/s00120-019-0912-7
Polifka, I., Agaimy, A., Herrmann, E., Spath, V., Trojan, L., Stoeckle, M.,... Hartmann, A. (2019). High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Human Pathology, 83, 212-223. https://dx.doi.org/10.1016/j.humpath.2018.08.006
Hirsch, K., Schwaiger, B., Kraske, S., & Wullich, B. (2019). Megaprepuce: presentation of a modified surgical technique with excellent cosmetic and functional results. Journal of Pediatric Urology. https://dx.doi.org/10.1016/j.jpurol.2019.05.018
Stoehr, R., Wendler, O.D., Giedl, J., Gaisa, N.T., Richter, G., Campean, V.,... Hartmann, A. (2019). No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis. Pathobiology, 86(2-3), 145-151. https://dx.doi.org/10.1159/000495251
Eckstein, M., Erben, P., Kriegmair, M.C., Worst, T.S., Weiss, C.-A., Wirtz, R.M.,... Erlmeier, F. (2019). Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European journal of cancer, 106, 234-243. https://dx.doi.org/10.1016/j.ejca.2018.11.007
Stoehr, C.G., Steffens, S., Polifka, I., Jung, R., Kahlmeyer, A., Ivanyi, P.,... Taubert, H. (2019). Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. Scientific Reports, 9. https://dx.doi.org/10.1038/s41598-018-38254-3
Kahlmeyer, A., Goebell, P., & Wullich, B. (2019). Presurgical assessments (Assessments vor Operationen). Urologe, 58(4), 373-380. https://dx.doi.org/10.1007/s00120-019-0888-3

Zuletzt aktualisiert 2016-05-05 um 05:06